相关实验视频

Updated: Jul 25, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

由2型炎症驱动的肺纤维化分子特征和阶段

Hamid Mattoo¹, Dinesh S Bangari², Sheila Cummings²

¹Precision Medicine and Computational Biology.

American journal of respiratory cell and molecular biology

|June 27, 2023

概括

2型炎症驱动系统性硬化 (SSc) 中的肺纤维化. 在炎症阶段用双特异性抗体向IL-4和IL-13,可以在小鼠模型中预防纤维化,为SSc-ILD提供治疗见解.

科学领域:

免疫学免疫学免疫学
肺部病理学肺部病理学
病理学病理学病理学

背景情况:

系统性硬化症 (SSc) 是一种渐进的多器官疾病,治疗选择有限.
在SSc病理生理学中IL-4和IL-13的作用,特别是在平衡炎症和纤维化方面,仍然不清楚.
与SSc相关的间歇性肺病 (SSc-ILD) 的现有治疗方法有限.

研究的目的:

为了研究2型炎症在纤维生成中的作用,使用Fos相关抗原2过度表达转基因 (FRA2-Tg) 鼠标模型.
在SSc-ILD中定义炎症和纤维化进展的分子和组织病理学特征.
评估在SSc-ILD中准IL-4和IL-13的治疗潜力.

主要方法:

使用FRA2-Tg小鼠表现出自发的,与年龄相关的肺纤维化.
在预先,炎症和纤维化的阶段特征化分子签名.
进行了体病理学分析,包括对乙酸和M2巨细胞的评估.
在炎症阶段给予针对IL-4和IL-13的双特异抗体.

主要成果:

FRA2-Tg小鼠表现出与人类SSc-ILD肺部重叠的分子特征,包括早期的细胞因子-细胞因子受体相互作用和Th2 / M2反应.
组织病理学揭示了进步性炎症与埃索因菲利亚和M2巨细胞,其次是显著的肺纤维化.
在炎症阶段针对IL-4和IL-13的抗体治疗几乎消除了肺纤维化.
该研究确定了从炎症过渡到纤维化的关键途径.

结论:

由Th2和M2巨细胞驱动的2型炎症是SSc-ILD中肺纤维化的一个关键驱动因素.
在炎症阶段向IL-4和IL-13代表了SSc-ILD的有前途的治疗策略.
FRA2-Tg小鼠作为一个有价值的临床前模型来评估SSc-ILD疗法.

关键词:

它们有IL-13和IL-13.IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL is is is is is is is is is is is is is is is is is is is what they are 有纤维化的纤维化.间歇性肺病间歇性肺病系统性硬化症系统性硬化症

更多相关视频

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

相关概念视频

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...